Research programme: anti-siglec-15 antibodies - OncoResponse
Latest Information Update: 22 Nov 2021
At a glance
- Originator OncoResponse
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Sialic acid binding immunoglobulin-like lectin inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Nov 2021 Pharmacodynamics data from preclinical studies in Cancer presented at the 36th Annual meeting of the Society for Immunotherapy of Cancer
- 10 Apr 2021 Preclinical trials in Cancer in USA (Parenteral) prior to April 2021
- 10 Apr 2021 Pharmacodynamics data from a preclinical trial in Cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)